Certara Services Archives

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-Bodnar2026 年 5 月 28 日

Publication

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…

Certara2026 年 5 月 21 日

Blog

Best Practices for pharma commercialization in market access

Learn best practices for your pharma commercialization strategy. See how to localize content in pharma…

Certara2026 年 5 月 12 日

Webinar

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Certara2026 年 5 月 8 日

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026 年 5 月 7 日

Press Coverage

The one-trial era: what the FDA’s shift signals for the future of drug development

The FDA is shifting toward approving drugs based on a single pivotal trial supported by…

Certara2026 年 5 月 6 日

Blog

Optimize Readiness for MHRA-NICE Aligned Pathway

Achieve HTA and regulatory success in the MHRA–NICE pathway through early evidence alignment.

Certara2026 年 5 月 1 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Certara 服务

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

尼拉帕利（Niraparib）群体药代动力学建模以评估不同吸收模型

Best Practices for pharma commercialization in market access

BioSpace webinar: Streamlining Nonclinical Development with FDA NAMs

Designing Drug Development Programs for Reimbursement Success

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

The one-trial era: what the FDA’s shift signals for the future of drug development

Optimize Readiness for MHRA-NICE Aligned Pathway

订阅时事通讯

快捷链接

解决方案

联系我们